David A. Siegel Nuvalent, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 152,200 shares of NUVL stock, worth $13.7 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
152,200
Previous 161,200
5.58%
Holding current value
$13.7 Million
Previous $12.2 Million
27.33%
% of portfolio
0.04%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding NUVL
# of Institutions
209Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.8 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$451 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$373 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$273 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$269 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.88B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...